Find the investors funding Health rounds
326,000+ VC, angel and family-office profiles — direct emails, check sizes and stage filters.
Switzerland's Nouscom bags €120 million to bring innovative cancer immunotherapy closer to clinical trials - EU-Startups
Nouscom is a biotechnology company developing novel cancer immunotherapies. Their innovative approach aims to bring advanced treatments closer to clinical trials. This funding will support the advancement of their pipeline.
Switzerland's Nouscom bags €120 million to bring innovative cancer immunotherapy closer to clinical trials EU-Startups
| Oct 09, 2026 | Klarent | $7.7M | Seed | Switzerland |
| Oct 09, 2026 | Besso | $4.5M | — | Switzerland |
| Oct 03, 2026 | Africa Finance Corporation | $431.0M | Debt | Switzerland |
| Oct 01, 2026 | FOOD FOUNDERS Studio | $4.0M | — | Switzerland |
You just read who funded Nouscom. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.